Aurinia Pharmaceuticals Inc. (AUPH) on Decifer

Decifer ranks AUPH number 12 of 271 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 20% a year, faster than 67 in 100 companies we measure.
• It keeps about 48 cents of every sales dollar as cash, safer than 98 in 100 companies we measure.
• It earns about 40% a year on the money put into the business, better than 96 in 100 companies we measure.
• It costs about 7 times its yearly profit; the middle of its industry is 20. Cheaper than 94 in 100 companies we measure, against their own industries.

The current read

The evidence on AUPH lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full AUPH research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.